…biib will be a better [FoB] partner [for MNTA] than Sandoz.
I disagree. When Wheeler spoke on the GS webcast of companies who “cannot get out of their own way in protecting their legacy businesses,” I immediately thought of BIIB. It is presumably one of the companies where executives worry unduly that their branded biologics could eventually be cannibalized by MNTA’s biogenerics.
Market Data 
Markets 
AI
